SKN | Barclays Raises Altria Target to $63 While Maintaining Underweight Rating

Key Takeaways

• Barclays raised its price target on Altria Group, Inc. to $63 from $57.
• The firm maintained an Underweight rating despite the higher valuation estimate.
• Altria reaffirmed its 2026 adjusted EPS guidance of $5.56–$5.72.
• Growth in next-generation nicotine products remains a key sector driver.

Barclays analyst Pallav Mittal lifted the firm’s price target on Altria Group to $63 from $57 while maintaining an Underweight rating on the shares. The higher target reflects adjustments to valuation assumptions as tobacco companies continue benefiting from strong pricing power and growing interest in next-generation nicotine products.

Despite the upward revision, the maintained Underweight stance suggests Barclays remains cautious about the stock’s risk-reward balance relative to other opportunities within the sector.

Earnings Guidance Reaffirmed

Altria recently participated in the Consumer Analyst Group of New York Conference and reiterated its 2026 adjusted diluted earnings-per-share guidance of $5.56 to $5.72. The projection represents expected growth of roughly 2.5% to 5.5% compared with the company’s 2025 base EPS of $5.42.

Management indicated that earnings growth will likely be weighted toward the second half of the year, supported by increasing cigarette import and export activity. The outlook also incorporates continued investment in contract manufacturing capabilities and assumes that the NJOY ACE product will not return to the marketplace in 2026.

Sector Trends and Strategic Positioning

Barclays noted that tobacco equities could continue to outperform as next-generation product categories expand. The transition toward alternative nicotine delivery systems has become an important strategic theme across the industry as companies adapt to changing consumer preferences and regulatory environments.

Altria’s diversified portfolio includes traditional combustible products as well as emerging nicotine platforms designed to capture growth in reduced-risk categories.

Outlook

Investor attention will likely remain focused on earnings durability, regulatory developments, and the company’s progress in expanding its next-generation product portfolio. While Barclays raised its valuation estimate, the firm’s cautious rating reflects continued scrutiny around long-term growth dynamics and competitive positioning within the evolving nicotine market.

For confidential discussions regarding tobacco sector valuation frameworks, regulatory risk modeling, next-generation nicotine product adoption trends, and income-oriented portfolio positioning within consumer staples equities, our senior advisory team is available for discreet consultation tailored to institutional and cross-border mandates.